GlobalData on MSN3d
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLCThe US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
GlobalData on MSN12d
Boehringer seeks approval of lung disease drug after second Phase III successBoehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S ...
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
An intron is a non-coding section of DNA or RNA within a gene that is removed during protein synthesis. ExpressionEdits is using introns – which had generally been derided as of no value – to enhance ...
The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback